Get access

Does use of tetracyclic antidepressant—mirtazapine reduce cancer risk in depression patients?

Authors

  • Li-Min Sun,

    1. Department of Radiation Oncology, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan
    Search for more papers by this author
    • Ming-Chia Lin and Li-Min Sun contributed equally to this work.

  • Ming-Chia Lin,

    1. Department of Nuclear Medicine, E-DA Hospital, Kaohsiung, Taiwan
    Search for more papers by this author
    • Ming-Chia Lin and Li-Min Sun contributed equally to this work.

  • Ji-An Liang,

    1. Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan
    2. Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
    Search for more papers by this author
  • Yen-Jung Chang,

    1. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
    Search for more papers by this author
  • Shih-Ni Chang,

    1. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
    Search for more papers by this author
  • Fung-Chang Sung,

    1. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
    2. Department of Public Health, China Medical University, Taichung, Taiwan
    Search for more papers by this author
  • Chih-Hsin Muo,

    Corresponding author
    1. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
    • Correspondence to: Dr. C-H. Kao, MD, Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University. 2 Yuh-Der Road, Taichung 404, Taiwan. Email: d10040@mail.cmuh.org.tw

      C-H. Muo M.S., China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. Email: A17776@mail.cmuh.org

    Search for more papers by this author
  • Chia-Hung Kao

    Corresponding author
    1. Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
    2. Department of Nuclear Medicine PET Center, China Medical University Hospital, Taichung, Taiwan
    • Correspondence to: Dr. C-H. Kao, MD, Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University. 2 Yuh-Der Road, Taichung 404, Taiwan. Email: d10040@mail.cmuh.org.tw

      C-H. Muo M.S., China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. Email: A17776@mail.cmuh.org

    Search for more papers by this author

ABSTRACT

Purpose

We conducted a nested case-control study to evaluate the association between risk of cancer and mirtazapine use in depression patients in Taiwan.

Methods

We obtained data from the Taiwan National Health Insurance Research Database to conduct a population-based nested case-control study. The study cohort included 16 897 patients diagnosed with depression between January 1, 2000 and December 31, 2008. We identified 530 cancer patients as the study group and matched 4 non-cancer subjects with each cancer patient by incident density, age, and sex. Odds ratios and 95% confidence intervals were estimated using multivariate conditional logistic regression analysis.

Results

Use of mirtazapine for depression did not have significant effect on overall cancer incidence (odds ratio: 1.03, 95% confidence interval: 0.72–1.48). Further analysis of annual mirtazapine dosages and the duration of mirtazapine use revealed no significant effect on cancer risk.

Conclusion

The findings of this population-based nested case-control study suggest that mirtazapine use may not provide a tumor suppression effect in humans such as that seen in the animal model. Future large-scale and in-depth investigations in this area are warranted. Copyright © 2013 John Wiley & Sons, Ltd.

Ancillary